Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Accumulated Expenses (2016 - 2025)

Capricor Therapeutics (CAPR) has 9 years of Accumulated Expenses data on record, last reported at $9.9 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $9.9 million; the TTM value through Sep 2025 reached $9.9 million, changed N/A, while the annual FY2024 figure was $4.9 million, N/A changed from the prior year.
  • Accumulated Expenses reached $9.9 million in Q3 2025 per CAPR's latest filing, up from $4.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $9.9 million in Q3 2025 and bottomed at $1.9 million in Q1 2025.